세계의 RNA 간섭(RNAi) 약물전달 시장 보고서 : 용도, 기술, 지역별(2025-2033년)
RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2025-2033
상품코드:1660964
리서치사:IMARC
발행일:2025년 02월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 RNA 간섭(RNAi) 약물전달 시장 규모는 2024년 998억 달러에 달했습니다. IMARC Group은 앞으로 시장이 2033년까지 4,661억 달러에 이르고, 2025년부터 2033년까지 17.75%의 성장률(CAGR)을 나타낼 것으로 예측했습니다.
리보 핵산 간섭(RNAi) 약물전달은 유전자 발현과 돌연변이를 모니터링하는 치료 솔루션을 말합니다. RNAi 약물전달은 일반적으로 정맥 주사, 피내 주사, 복강 내 주사, 국소 전달 방법으로 투여됩니다. 나노입자, 폐, 핵산, 앱타머 등의 약물전달 기술이 포함됩니다. 이 기술은 진핵 생물에서 유전자 기능을 분석하고 치료 유전자 침묵 솔루션을 개발하는 데에도 사용됩니다. 그 결과 RNAi 약물전달은 감염, 만성 대사 질환, 심혈관 질환, 신경 질환, 비뇨기 질환, 종양 질환, 안과 질환의 치료에 널리 사용됩니다.
암과 심혈관 질환(CVD)과 같은 만성 질환과 유전성 질환의 세계 유병률 증가는 시장 성장을 가속하는 중요한 요소 중 하나입니다. 게다가 이러한 병에 걸리기 쉬운 노년 인구가 증가하고 있는 것도 시장의 성장을 뒷받침하고 있습니다. 이에 따라 코로나바이러스 감염(COVID-19)이 세계에 계속 확산되고 있기 때문에 RNAi 약물전달 기술에 대한 수요가 크게 증가하고 있습니다. 앱타머 약물전달 시스템과 같은 표적화 전달 방법은 바이러스 항원의 발현을 억제할 수 있는 저분자 간섭 RNA(siRNA)에 의해 유도되기 때문에 항바이러스제물의 투여에 절대적인 지지를 얻고 있습니다. 또한 혁신적인 합성 전달 캐리어 및 바이오 벡터 개발과 같은 다양한 기술의 발전이 시장 성장을 가속할 것으로 예상됩니다. siRNA와 마이크로RNA(miRNA)를 포함한 나노담체는 개별화된 의약품의 개발과 변화된 세포분자와 대사산물의 동정에 매우 중요합니다. 나노기술 및 분자진단 분야에서 광범위한 R&D 활동을 비롯한 기타 요인들은 의료 인프라의 전반적인 개선과 함께 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
세계의 RNA 간섭(RNAi) 약물전달 시장은 지금까지 어떻게 추이했고 향후 몇 년간 어떻게 추이할 것인가?
The global RNA interference (RNAi) drug delivery market size reached USD 99.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 466.1 Billion by 2033, exhibiting a growth rate (CAGR) of 17.75% during 2025-2033.
Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.
The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
Breakup by Application:
Infectious Disease
Cardiology
Oncology
Neurology
Ophthalmology
Urology
Metabolic Disorders
Others
Breakup by Technology:
Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc, and Sirnaomics Inc.
Key Questions Answered in This Report:
How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the technology?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global RNA Interference (RNAi) Drug Delivery Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Application
6.1 Infectious Disease
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Cardiology
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Oncology
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Neurology
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Ophthalmology
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Urology
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Metabolic Disorders
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Others
6.8.1 Market Trends
6.8.2 Market Forecast
7 Market Breakup by Technology
7.1 Nanoparticle Drug Delivery
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Pulmonary Drug Delivery
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Nucleic Acid Drug Delivery
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Aptamer Drug Delivery
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Alnylam Pharmaceuticals Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Arrowhead Pharmaceuticals Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.3 CureVac AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.4 Dicerna Pharmaceuticals Inc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.5 Gradalis Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Ionis Pharmaceuticals Inc
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Merck & Co. Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Moderna Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
